Utilization of Non-human Viruses as Recombinant Vector Vaccines against Newly Emerging Human Viral Diseases

Dear Colleagues,

The emergence of new viral diseases continues to pose ongoing global health challenges, underscoring the need for efficient vaccines. Traditional vaccine development methods are often time-consuming and expensive. However, there is a growing interest in utilizing non-human viruses as recombinant vector vaccines for emerging human viral diseases. These vectors offer several advantages, including a reduced risk of recombination with wild-type human viruses and potentially lower pathogenicity. Non-human viruses, such as herpesviruses, adenoviruses, poxviruses, and baculoviruses, are being investigated as potential vectors for delivering antigens from various pathogens. They can be genetically modified to express specific antigens, stimulating an immune response that protects against the target pathogen. Using non-human viruses as vectors also circumvents issues related to pre-existing immunity to human viruses, which can limit the effectiveness of traditional viral vector vaccines. Overall, non-human viruses used as recombinant vector vaccines offer reduced recombination risks, lower pathogenicity, and the ability to target multiple pathogens simultaneously. This enables rapid vaccine development and deployment.

I am delighted to invite you to contribute your research to this Special Issue, titled “Utilization of Non-Human Viruses as Recombinant Vector Vaccines Against Newly Emerging Human Viral Diseases”. This Special Issue aims to showcase recent research and advancements in using non-human viruses as vectors, highlighting their benefits, challenges, and future directions.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: non-human viruses, recombinant vector vaccines, emerging human viral diseases, vaccine development, immunogenicity, the immune response, comparative vaccine studies, and clinical trials.

I look forward to receiving your contributions.

Dr. Dayan Wang
Dr. Abdo Said
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• recombinant vector vaccines
• non-human viruses (herpesviruses, adenoviruses, poxviruses, and baculoviruses)
• vaccine development
• immunogenicity
• immune response
• comparative vaccine studies
• clinical trials